Abstract
Psoriasis, an incurable disease characterized by periods of disease relapse and remission, often requires long-term treatment to manage symptoms. The risk of serious cumulative toxicity precludes long-term administration with currently available systemic therapies. Efalizumab is an IgG1 humanized monoclonal antibody in development to address the need for a safe, long-term therapy for continuous control of plaque psoriasis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
